The phase III WATERFALL study found that 50 mg of zuranolone (SAGE-217/BIIB125) — a once-daily investigational oral agent given for 2 weeks — significantly reduced depressive symptoms by day 15 versus placebo in patients with major depressive disorder, Sage Therapeutics and Biogen announced.
Using cannabis in middle to late adolescence, specifically ages 14 to 19, was tied to accelerated age-related cortical thinning, particularly in the prefrontal regions. (JAMA Psychiatry)
A phase II trial found that just a single 1-hour treatment of breathing in a combination of oxygen and laughing gas improved depressive symptoms in people with treatment-resistant depression. “That we saw rapid improvements in many such patients in the study suggests nitrous oxide may help people with really severe, resistant depression,” said senior study author Charles Conway, MD, of Washington University School of Medicine in St. Louis. (Science Translational Medicine)
The investigational dementia-related psychosis agent xanomeline-trospium (KarXT) was deemed safe and tolerable in a phase Ib trial of healthy elderly participants, Karuna Therapeutics announced.
No surprise here: working in a toxic environment that doesn’t prioritize employee mental health increased the rate of depression by threefold among workers. (BMJ Open)
In related news, people who suffer from multiple respiratory conditions saw a higher risk for both depression and anxiety. “Through the use of approaches that integrate care for physical and mental health we may be able to help lessen the impact of multiple physical health problems,” said study author Jayati Das-Munshi, PhD, of King’s College London. (Lancet Regional Health — Europe)
The Washington Post detailed the brutal physical restraint practices endured by institutionalized psychiatric patients in Japan.
Cindy Crusto, PhD, has become the first Black female professor in the history of Yale Psychiatry, the university’s School of Medicine announced.